Last reviewed · How we verify
EXO-CD24
At a glance
| Generic name | EXO-CD24 |
|---|---|
| Also known as | Exosomes Overexpressing CD24 |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS (PHASE2)
- Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19 (PHASE2)
- Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXO-CD24 CI brief — competitive landscape report
- EXO-CD24 updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI